Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
drug eruptions/tyrosine
Veza se sprema u međuspremnik
Stranica 1 iz 16 rezultatima
Purpuric drug eruptions induced by EGFR tyrosine kinase inhibitors are associated with IQGAP1-mediated increase in vascular permeability.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used as a treatment for non-small cell lung cancer. There have been some reports of EGFR-TKIs being associated with vascular adverse events. We found that EGFR-TKIs decreased the proliferation of HMEC-1 (immortalized human
Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
UNASSIGNED
Purpuric skin lesions have only rarely been reported in patients receiving epidermal growth factor receptor inhibitors. However, their clinical and histopathologic presentations have varied considerably.
UNASSIGNED
To characterize purpuric skin eruptions caused by epidermal growth factor
Immunohistochemical characterization of cutaneous drug eruptions by STI571.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
BACKGROUND
STI571, a selective BCR-ABL tyrosine kinase inhibitor, is a promising new drug for chronic myelogenous leukemia (CML). However, the drug has been reported to be associated with adverse cutaneous drug eruptions with high frequency.
OBJECTIVE
In this study, the characteristics of the
Lichenoid drug eruption caused by imatinib mesylate in a Chinese patient with gastrointestinal stromal tumor.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Imatinib mesylate, the first agent approved for the treatment of unresectable or metastatic gastrointestinal stromal tumor, is a tyrosine kinase inhibitor targeting (KIT) and the platelet-derived growth factor receptor-α and -β. However, imatinib administration can be accompanied by various adverse
Imatinib mesylate-induced lichenoid drug eruption.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). Since then, the number of indicated uses for imatinib has substantially increased. It is increasingly important that dermatologists
Fixed drug eruption related to sunitinib: a case report.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor. It has been approved for the treatment of gastro-intestinal stromal tumor and advanced renal cell carcinoma. Fixed drug eruption related to sunitinib is a rare cutaneous adverse drug reaction.
Cutaneous drug eruptions induced by sorafenib: a case series.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Sorafenib, an epidermal growth factor receptor inhibitor, is a novel treatment used for malignancies resistant to traditional chemotherapy. Epidermal growth factor receptors (EGFR) are a family of 4 transmembrane tyrosine kinase receptors that, via signal transduction pathways, mediate cell growth,
Ponatinib-induced ichthyosiform drug eruption: insights into acquired ichthyosis.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Cutaneous adverse events are commonly experienced with use of tyrosine kinase inhibitors in the treatment of leukemia and typically include nonspecific cutaneous eruptions and xerosis. We report the case of a man who experienced an ichthyosiform drug eruption while taking ponatinib, a
Therapeutic hotline. A rare vandetanib-induced photo-allergic drug eruption.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Vandetanib is an inhibitor of the vascular endothelial growth factor receptor 2 tyrosine kinase and the epidermal growth factor receptor tyrosine kinase, recently used in the treatment of different tumors. We describe a case of a photo-allergic reaction to vandetanib in an 80-year-old Caucasian
Purpuric drug eruption and alopecia induced by erlotinib.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
We herein report a case of diffuse alopecia with pustules on the scalp and purpuric lesions on the lower legs in a Japanese man after treatment with erlotinib. This is a unique case in which rare skin eruptions simultaneously occurred. We discuss herein a combination of skin eruptions as an adverse
Vandetanib-induced Phototoxic Drug Eruption Treated with Polypodium Leucotomos Extract: A Case Report and Review of the Literature.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Vandetanib is a tyrosine kinase inhibitor approved by the United States Food and Drug Administration for the treatment of metastatic medullary thyroid cancer. It has been linked to a variety of dermatologic reactions, including photosensitivity. We describe the case of a 55-year-old man who
[Peritoneal dissemination from gastrointestinal stromal tumor of small intestine responding completely to imatinib mesylate (STI 571)].
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
The prognosis of metastatic or recurrent GISTs is poor, because these tumors resist chemotherapy and radiotherapy. We report a patient with recurrent GIST who underwent molecularly targeted therapy with imatinib, a novel oral tyrosine kinase inhibitor. A 64-year-old man presented with large
Mycosis fungoides-like reaction in a patient treated with Gleevec.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
BACKGROUND
Gleevec trade mark is a protein tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumor. Currently, Gleevec is also being used in protocols for treatment of other malignancies such as melanoma. A few, non-descript cutaneous
Demodex folliculitis mimicking acute graft-vs-host disease.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
OBJECTIVE
Acute graft-vs-host disease (GVHD) typically requires high-dose systemic steroids as first-line treatment. Like drug eruptions, viral exanthema, and toxic erythema of chemotherapy, Demodex folliculitis is a clinical mimicker of acute GVHD and requires nonimmunosuppressive therapy. This
Crizotinib-associated erythema multiforme in a lung cancer patient.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Crizotinib is an oral small-molecule anaplastic lymphoma kinase (ALK) tyrosine-kinase inhibitor for the treatment of ALK-positive non-small-cell lung cancer (NSCLC). A 63-year old woman with postoperative relapsed ALK-positive NSCLC was treated with crizotinib. Erythema multiforme (EM) occurred one
Najkompletnija baza ljekovitog bilja potpomognuta znanošću
- Radi na 55 jezika
- Biljni lijekovi potpomognuti znanošću
- Prepoznavanje bilja slikom
- Interaktivna GPS karta - označite bilje na mjestu (uskoro)
- Pročitajte znanstvene publikacije povezane s vašom pretragom
- Pretražite ljekovito bilje po učincima
- Organizirajte svoje interese i budite u toku s istraživanjem vijesti, kliničkim ispitivanjima i patentima
Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Svi podaci temelje se na objavljenim znanstvenim istraživanjima
